Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher L Brooks

Showing results (11-20 of 19) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 19 results.
Cell Cycle (Georgetown, Tex.)|February 21, 2004
Monoubiquitination: the signal for p53 nuclear export?Christopher L Brooks, Muyang Li, Wei Gu
The Journal of Biological Chemistry|November 8, 2002
Acetylation of p53 inhibits its ubiquitination by Mdm2Muyang Li, Jianyuan Luo, Christopher L Brooks, et al.
Molecular Cell|April 1, 2004
A dynamic role of HAUSP in the p53-Mdm2 pathwayMuyang Li, Christopher L Brooks, Ning Kon, et al.
Science (New York, N.Y.)|December 13, 2003
Mono- versus polyubiquitination: differential control of p53 fate by Mdm2Muyang Li, Christopher L Brooks, Foon Wu-Baer, et al.
Advances in Therapy|March 14, 2022
Clinical Remission in Severe Asthma: A Pooled Post Hoc Analysis of the Patient Journey with BenralizumabAndrew Menzies-Gow, Flavia L Hoyte, David B Price, et al.
Advances in Therapy|June 22, 2022
A Response to: Letter to the Editor Regarding "Clinical Remission in Severe Asthma: A Pooled Post Hoc Analysis of the Patient Journey with Benralizumab"Andrew Menzies-Gow, Flavia L Hoyte, David B Price, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 12, 2022
Long-Term Benefits of Tagraxofusp for Patients With Blastic Plasmacytoid Dendritic Cell NeoplasmNaveen Pemmaraju, Kendra L Sweet, Anthony S Stein, et al.
The New England Journal of Medicine|April 25, 2019
Tagraxofusp in Blastic Plasmacytoid Dendritic-Cell NeoplasmNaveen Pemmaraju, Andrew A Lane, Kendra L Sweet, et al.
The Journal of Clinical Investigation|August 23, 2019
DNA methyltransferase inhibition overcomes diphthamide pathway deficiencies underlying CD123-targeted treatment resistanceKatsuhiro Togami, Timothy Pastika, Jason Stephansky, et al.
Pageof 2

Showing results (11-20 of 19) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 19 results.
Cell Cycle (Georgetown, Tex.)|February 21, 2004
Monoubiquitination: the signal for p53 nuclear export?Christopher L Brooks, Muyang Li, Wei Gu
The Journal of Biological Chemistry|November 8, 2002
Acetylation of p53 inhibits its ubiquitination by Mdm2Muyang Li, Jianyuan Luo, Christopher L Brooks, et al.
Molecular Cell|April 1, 2004
A dynamic role of HAUSP in the p53-Mdm2 pathwayMuyang Li, Christopher L Brooks, Ning Kon, et al.
Science (New York, N.Y.)|December 13, 2003
Mono- versus polyubiquitination: differential control of p53 fate by Mdm2Muyang Li, Christopher L Brooks, Foon Wu-Baer, et al.
Advances in Therapy|March 14, 2022
Clinical Remission in Severe Asthma: A Pooled Post Hoc Analysis of the Patient Journey with BenralizumabAndrew Menzies-Gow, Flavia L Hoyte, David B Price, et al.
Advances in Therapy|June 22, 2022
A Response to: Letter to the Editor Regarding "Clinical Remission in Severe Asthma: A Pooled Post Hoc Analysis of the Patient Journey with Benralizumab"Andrew Menzies-Gow, Flavia L Hoyte, David B Price, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 12, 2022
Long-Term Benefits of Tagraxofusp for Patients With Blastic Plasmacytoid Dendritic Cell NeoplasmNaveen Pemmaraju, Kendra L Sweet, Anthony S Stein, et al.
The New England Journal of Medicine|April 25, 2019
Tagraxofusp in Blastic Plasmacytoid Dendritic-Cell NeoplasmNaveen Pemmaraju, Andrew A Lane, Kendra L Sweet, et al.
The Journal of Clinical Investigation|August 23, 2019
DNA methyltransferase inhibition overcomes diphthamide pathway deficiencies underlying CD123-targeted treatment resistanceKatsuhiro Togami, Timothy Pastika, Jason Stephansky, et al.
Pageof 2